Arcutis Biotherapeutics reports Q1 EPS (20c), consensus (21c)

Reports Q1 revenue $65.85M, consensus $62.48M. “In the first quarter we again delivered excellent performance driven by strong demand growth for our ZORYVE portfolio, which offers a distinct and compelling value proposition and provides healthcare providers and their patients with an effective and safe alternative to steroids. We have broad commercial coverage, are continuing to expand Medicaid coverage – with more than 1 in 2 recipients having coverage – and are maintaining our gross-to-net in the 50s,” said Frank Watanabe, president and chief executive officer. “With our team’s execution of our strategy, strong financial position, multiple upcoming catalysts and market expansion opportunities, including additional indications and further coverage expansion for ZORYVE, as well as a promising pipeline, we are confident in our continued growth in 2025 and beyond.”